The cystic fibrosis gut as a potential source of multidrug resistant pathogens-Reference-Cited by-同舟云学术

The cystic fibrosis gut as a potential source of multidrug resistant pathogens

Published:2021-05 Issue:3 Volume:20 Page:413-420
ISSN:1569-1993
Container-title:Journal of Cystic Fibrosis
language:en
Short-container-title:Journal of Cystic Fibrosis

Author:

Taylor Steven L.,Leong Lex E.X.,Sims Sarah K.,Keating Rebecca L.^ORCID,Papanicolas Lito E.,Richard Alyson,Mobegi Fredrick M.,Wesselingh Steve,Burr Lucy D.,Rogers Geraint B.

Funder

National Health and Medical Research Council

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Reference44 articles.

1. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis–the TOPIC study: a randomised controlled trial;Smyth;Lancet,2005

2. Case-control study of acute renal failure in patients with cystic fibrosis in the UK;Smyth;Thorax,2008

3. Opportunistic bacteria confer the ability to ferment prebiotic starch in the adult cystic fibrosis gut;Wang;Gut Microbes,2019

4. Pseudomonas aeruginosa antibiotic resistance in Australian cystic fibrosis centres;Smith;Respirology,2016

5. Antibiotic multidrug resistance in the cystic fibrosis airway microbiome is associated with decreased diversity;Hahn;Heliyon,2018

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exposure to doxycycline increases risk of carrying a broad range of enteric antimicrobial resistance determinants in an elderly cohort;Journal of Infection;2024-10

2. Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis;Journal of Cystic Fibrosis;2024-05

3. Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor;mBio;2024-02-14

4. Understanding the clinical implications of the “non-classical” microbiome in chronic lung disease: a viewpoint;European Respiratory Journal;2024-02

5. Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis;2024-02-01